Minimum 20 minute delay
Minimum 20 minute delay
Aequus Pharmaceuticals Inc. (TSX-V: AQS) is a rapidly growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ management team has a proven track record of managing drug development from product validation through commercial launch, including clinical development and regulatory approval processes as well as launching and marketing products both directly and with commercial partners.
Commercial strategy. Aequus has a pipeline of commercial and near-commercial products that have been brought in through an acquisition or license to be marketed in Canada. We will continue to expand our commercial pipeline with high quality, differentiated products including patented products, branded generics, and reformulated novel-delivery products within focused therapeutic areas. Aequus continues to evaluate and develop additional product candidates that the Company believes to have significant commercial potential through both internal research and development efforts and external collaborations. ( View Aequus’ full product pipeline…)
Development strategy. Aequus is developing several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. These products combine new delivery technologies, such as transdermal patches, with currently approved medicines that are limited by their current route of delivery. Aequus’ lead development stage product, AQS-1301, a once-weekly transdermal formulation of aripiprazole, is currently entering the second phase of a two-part Phase I study, with results expected Q1 2017. This product is anticipated to provide patients with an easy to use and non-invasive long acting alternative to their current daily dosing schedule, with the goal of reducing their risk of relapsing into an acute episode. (Read more about AQS-1301…)
Aequus has two preclinical programs currently in formulation optimization, AQS-1302 and AQS-1303, each expected to enter clinical studies in 2017. AQS-1302 is being advanced for the potential treatment of epilepsy with a once-weekly transdermal application to provide patients with steady-state delivery of their medication; this product is expected to reduce their risk of experiencing breakthrough seizures (Read more about AQS-1302…).
AQS-1303 is in development for the management of Nausea and Vomiting of Pregnancy (NVP) and is expected to provide consistent anti-emetic control while eliminating the risk of missed doses due to emesis (vomiting) (Read more about AQS-1303…).
Committed to acquiring, licensing and promoting differentiated prescription products within Canada. Aequus intends to commercialize its internal programs within Canada with specialty sales forces and to establish strategic partnerships to accelerate and maximize the potential of its product candidates worldwide.
Aequus depends on the compliance of its directors, officers, consultants, associates and employees of Aequus and each of its subsidiaries to conduct business in line with its Code of Conduct and Ethics. To review the Code of Conduct and Ethics, click here.